GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...

Among the key problems highlighted in the report is that too much of the NHS budget is being spent in hospitals, with too ...

On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health. Executives from AstraZeneca, ...

Moderna said the changes will reduce the cumulative spend on R&D between 2025 and 2028 to $16 billion from $20 billion, and allow it to break even financially in 2028.

Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the drug negotiation provisions in the Inflation Reduction Act. The ...

In the study, MILTON was used to analyse 3,200 diseases and achieved a high prediction score for 1,091 of them. It can be ...

Whilst ePI brings with it a whole host of benefits, certain barriers such as limited internet access or varying levels of ...

The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Ben Hargreaves finds that a new variant of the virus is spreading more rapidly, and the response is ...

In the realm of scientific communication, traditional posters serve as critical conduits for HCPs seeking the latest ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

In the new SCALE Kids study, which has been published in the New England Journal of Medicine, a daily 3mg dose of Saxenda ...